Colistin Market Size and Forecast (2021 - 2034), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Formulation [Injectables (IV or IM), Oral, Topical Formulations, and Inhalation Solutions], Indication [Human Health (Bl

The Colistin market size is expected to grow from US$ 337.00 million in 2025 to US$ 510.94 million by 2034; it is projected to register a CAGR of 4.8% during 2026–2034. The increased multidrug-resistant Gram-negative infections in human healthcare, sustained veterinary demand in livestock and poultry farming are noteworthy factors contributing to the expansion of the colistin market. Additionally, the advancements in novel formulations and delivery systems as well as a rise in combination and synergistic therapies are projected to bring new market drifts in the near future.

The advancement in novel formulations and delivery systems includes the development of liposomal colistin, which encapsulates the drug to reduce nephrotoxicity and improve targeted delivery, particularly for systemic infections. For instance, liposomal formulations are being explored to broaden treatment options beyond traditional injectables, with inhalable and topical preparations gaining traction for respiratory and localized infections. A large-scale clinical trial launched in 2022 evaluated novel colistin formulations in combination therapies, demonstrating improved outcomes in severe cases. The high-purity colistin sulfate segment holds a major share, driven by therapeutic and research applications. In chronic lung infections, nebulized and topical colistin delivery experienced an increase in global clinical trials in 2023, focusing on conditions such as cystic fibrosis and ventilator-associated pneumonia. Advancements in nanotechnology are focused on enhancing colistin's activity, reducing the likelihood of resistance through improved drug penetration. These innovations are expected to sustain demand in niche applications where alternatives are limited, particularly in high-burden regions such as Asia Pacific, which anticipates a major share owing to expanding healthcare infrastructure. Photodynamic therapy (PDT) as an adjunctive method is also being integrated to boost colistin's effectiveness against resistant strains. Overall, innovations in novel formulations and delivery systems aimed at minimizing toxicity, improving bioavailability, and enhancing efficacy against multidrug-resistant infections are expected to be the key trends in the coming years.

Distribution Channel -Based Insights

Based on distribution channel, the colistin market is segmented into hospital pharmacy, retail pharmacy, online channel, and other distribution channel. The hospital pharmacy segment held the largest market share in 2025. Hospital pharmacies serve as the primary distribution channel for colistin in human healthcare, particularly for treating severe multidrug-resistant Gram-negative infections in intensive care settings, where the drug is administered intravenously or via inhalation for conditions like ventilator-associated pneumonia and sepsis. For example, colistin methanesulfonate is commonly stocked in hospital formularies for last-resort use against pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa, with dosing protocols adjusted for renal function to mitigate nephrotoxicity. In 2023, hospital pharmacies facilitated treatments for over 3.2 million ICU-related infections requiring polymyxin-class antibiotics, with countries like Brazil, Indonesia, and Russia reporting over 37% of severe cases resistant to carbapenems, driving demand. A study indicated that hospital channels account for approximately 60% of colistin distribution in human medicine, supported by direct procurement from manufacturers like Xellia Pharmaceuticals and Fresenius Kabi. Trends show increasing adoption of combination therapies in hospitals, enhancing efficacy while stewardship programs monitor usage to curb resistance. In Europe, the European Medicines Agency regulates hospital supplies, ensuring high-purity formulations. Key players such as Hikma Pharmaceuticals and Teva Pharmaceutical Industries supply through contractual collaborations, emphasizing supply chain resilience amid regulatory frameworks. This channel's dominance stems from colistin's role in acute care, though toxicity concerns limit broader outpatient shifts.

The World Health Organization, Centers for Disease Control and Prevention (CDC), Pan-Canadian Action Plan on Antimicrobial Resistance, European Centre for Disease Prevention and Control (ECDC), UK Health Security Agency (UKHSA), Agency for Health and Food Safety, the National Public Health Organization, Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report, the Australia and New Zealand Group on Antimicrobial Resistance (AGAR), the Ministry of Health, and Labour and Welfare (MHLW) are among the primary and secondary sources referred to while preparing the colistin market report.

Reasons to Buy

Saves and reduces time required for identifying the market growth, size, leading players, and segments in the global Colistin market.
Highlights key business priorities to assist companies in realigning their business strategies
Emphasizes key findings and recommendations that uncover emerging industry trends in the global Colistin market, enabling stakeholders across the value chain to craft effective long-term strategies
Develop/modify business expansion plans by analyzing substantial growth prospects in mature and emerging markets
Scrutinizes in-depth global Colistin market trends, along with factors driving the market, as well as those hindering it
Enhances the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution Show more